{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:42:40Z","timestamp":1790217760259,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011915","name":"Taylor\u2019s University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013041","name":"Vice-Chancellor for Research, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10495-026-02346-7","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:52:48Z","timestamp":1778161968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multi-targeted therapeutic strategy for triple-negative breast cancer: the tumor-targeting peptide p28 enhances chemotherapy, induces apoptosis, crosses the blood\u2013brain barrier, and suppresses metastasis"],"prefix":"10.1007","volume":"31","author":[{"given":"Haniyeh","family":"Abuei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Pei","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Mojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin Mosleh","family":"Shirazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Sharifzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"11","key":"2346_CR1","first-page":"1233","volume":"22","author":"C Anders","year":"2008","unstructured":"Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22(11):1233","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"2346_CR2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.18632\/oncotarget.12284","volume":"8","author":"H Yao","year":"2016","unstructured":"Yao H et al (2016) Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 8(1):1913","journal-title":"Oncotarget"},{"key":"2346_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","volume":"161","author":"X Li","year":"2017","unstructured":"Li X et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279\u2013287","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2346_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176\u2013198","journal-title":"Cancer Discov"},{"key":"2346_CR5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","volume":"8","author":"S Al-Mahmood","year":"2018","unstructured":"Al-Mahmood S et al (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8:1483\u20131507","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"2346_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.21037\/atm.2018.04.35","volume":"6","author":"EM Brosnan","year":"2018","unstructured":"Brosnan EM, Anders CK (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6(9):163","journal-title":"Ann Transl Med"},{"key":"2346_CR7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S293685","author":"Y Lv","year":"2021","unstructured":"Lv Y et al (2021) Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets. OncoTargets Ther. https:\/\/doi.org\/10.2147\/OTT.S293685. (1178-6930)","journal-title":"OncoTargets Ther"},{"key":"2346_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-017-4526-8","volume":"167","author":"O Kaidar-Person","year":"2018","unstructured":"Kaidar-Person O et al (2018) Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Res Treat 167:479\u2013483","journal-title":"Breast Cancer Res Treat"},{"key":"2346_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108522","volume":"250","author":"SU Khan","year":"2023","unstructured":"Khan SU et al (2023) Cancer metastasis: Molecular mechanisms and clinical perspectives. Pharmacol Ther 250:108522","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2346_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU et al (2024) Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal 22(1):109","journal-title":"Cell Commun Signal"},{"issue":"6119","key":"2346_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1126\/science.1228522","volume":"339","author":"M Yu","year":"2013","unstructured":"Yu M et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580\u2013584","journal-title":"Science"},{"issue":"4","key":"2346_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.maturitas.2009.06.010","volume":"63","author":"SK Pal","year":"2009","unstructured":"Pal SK, Mortimer J (2009) Triple-negative breast cancer: novel therapies and new directions. Maturitas 63(4):269\u2013274","journal-title":"Maturitas"},{"issue":"10","key":"2346_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","volume":"20","author":"BK Linderholm","year":"2009","unstructured":"Linderholm BK et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20(10):1639\u20131646 (0923-7534)","journal-title":"Ann Oncol"},{"key":"2346_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-188","volume":"9","author":"A K\u00f6hrmann","year":"2009","unstructured":"K\u00f6hrmann A et al (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 9:1\u201320","journal-title":"BMC Cancer"},{"key":"2346_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-07860-2","volume":"21","author":"H Jiang","year":"2021","unstructured":"Jiang H, Li H (2021) Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer 21:1\u201313","journal-title":"BMC Cancer"},{"key":"2346_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-348","volume":"11","author":"P Bostr\u00f6m","year":"2011","unstructured":"Bostr\u00f6m P et al (2011) MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 11:1\u20138","journal-title":"BMC Cancer"},{"issue":"34","key":"2346_CR17","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin K-M (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25(34):4798\u20134811","journal-title":"Oncogene"},{"issue":"9","key":"2346_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/bjc.2011.111","volume":"104","author":"J Wood","year":"2011","unstructured":"Wood J et al (2011) Co-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis. Br J Cancer 104(9):1459\u20131471 (1532-1827)","journal-title":"Br J Cancer"},{"issue":"3","key":"2346_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neo.2018.01.001","volume":"20","author":"CK Das","year":"2018","unstructured":"Das CK et al (2018) BAG3 overexpression and cytoprotective autophagy mediate apoptosis resistance in chemoresistant breast cancer cells. Neoplasia 20(3):263\u2013279","journal-title":"Neoplasia"},{"issue":"12","key":"2346_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000893","volume":"2","author":"D Lane","year":"2010","unstructured":"Lane D, Levine A (2010) p53 research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2(12):a000893","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2346_CR21","doi-asserted-by":"crossref","unstructured":"Brigham et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370","DOI":"10.1038\/nature11412"},{"key":"2346_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canlet.2017.09.053","volume":"414","author":"NC Synnott","year":"2018","unstructured":"Synnott NC et al (2018) Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett 414:99\u2013106","journal-title":"Cancer Lett"},{"issue":"1","key":"2346_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger AC, Fersht AR (2016) The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem 85(1):375\u2013404","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"2346_CR24","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275\u20131281","journal-title":"J Clin Oncol"},{"issue":"7","key":"2346_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145\u20131153","journal-title":"J Clin Oncol"},{"issue":"3","key":"2346_CR26","first-page":"2905","volume":"17","author":"F Qi","year":"2019","unstructured":"Qi F, Qin W-X, Zang Y-S (2019) Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways. Oncol Lett 17(3):2905\u20132914","journal-title":"Oncol Lett"},{"issue":"1","key":"2346_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00197-2","volume":"6","author":"A Marra","year":"2020","unstructured":"Marra A et al (2020) Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer 6(1):54","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2346_CR28","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171357","volume":"38","author":"NKR Chalakur-Ramireddy","year":"2018","unstructured":"Chalakur-Ramireddy NKR, Pakala SB (2018) Combined drug therapeutic strategies for the effective treatment of triple negative breast cancer. Biosci Rep 38(1):BSR20171357","journal-title":"Biosci Rep"},{"issue":"8","key":"2346_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2174\/1570163817666200518081955","volume":"20","author":"MA Mir","year":"2020","unstructured":"Mir MA et al (2020) Targeting different pathways using novel combination therapy in triple negative breast cancer. Curr Cancer Drug Targets 20(8):586\u2013602","journal-title":"Curr Cancer Drug Targets"},{"issue":"19","key":"2346_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911046","volume":"23","author":"Y Wang","year":"2022","unstructured":"Wang Y, Minden A (2022) Current molecular combination therapies used for the treatment of breast cancer. Int J Mol Sci 23(19):11046","journal-title":"Int J Mol Sci"},{"key":"2346_CR31","doi-asserted-by":"crossref","unstructured":"Jassim A et al. (2024) Natural language processing charts transcriptome evolution to design combination cancer therapies. bioRxiv, p 2024.04. 09.585681","DOI":"10.2139\/ssrn.4776717"},{"issue":"23","key":"2346_CR32","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","volume":"16","author":"PR Lockman","year":"2010","unstructured":"Lockman PR et al (2010) Heterogeneous blood\u2013tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16(23):5664\u20135678","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2346_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1021\/acs.bioconjchem.1c00123","volume":"32","author":"DA Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a DA et al (2021) Penetrating the blood-brain barrier with new peptide\u2013porphyrin conjugates having anti-HIV activity. Bioconjug Chem 32(6):1067\u20131077","journal-title":"Bioconjug Chem"},{"key":"2346_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2017.02.006","volume":"250","author":"S Dissanayake","year":"2017","unstructured":"Dissanayake S et al (2017) Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J Control Release 250:62\u201376","journal-title":"J Control Release"},{"issue":"25","key":"2346_CR35","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.1073\/pnas.0403317101","volume":"101","author":"P Laakkonen","year":"2004","unstructured":"Laakkonen P et al (2004) Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A 101(25):9381\u20139386","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2346_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/0008-5472.CAN-08-2932","volume":"69","author":"BN Taylor","year":"2009","unstructured":"Taylor BN et al (2009) Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res 69(2):537\u2013546","journal-title":"Cancer Res"},{"issue":"1","key":"2346_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad042","volume":"5","author":"S Mander","year":"2023","unstructured":"Mander S et al (2023) The brain-penetrant cell-cycle inhibitor p28 sensitizes brain metastases to DNA-damaging agents. Neuro-Oncol Adv 5(1):vdad042","journal-title":"Neuro-Oncol Adv"},{"issue":"10","key":"2346_CR38","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1535-7163.MCT-09-0444","volume":"8","author":"T Yamada","year":"2009","unstructured":"Yamada T et al (2009) A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol Cancer Ther 8(10):2947\u20132958","journal-title":"Mol Cancer Ther"},{"key":"2346_CR39","first-page":"1799","volume":"9","author":"E Coppari","year":"2014","unstructured":"Coppari E et al (2014) A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins. Int J Nanomedicine 9:1799","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"2346_CR40","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1021\/mp400221r","volume":"10","author":"T Yamada","year":"2013","unstructured":"Yamada T (2013) p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol Pharm 10(9):3375\u20133383","journal-title":"Mol Pharm"},{"issue":"5","key":"2346_CR41","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/bjc.2013.74","volume":"108","author":"MA Warso","year":"2013","unstructured":"Warso MA et al (2013) A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer 108(5):1061\u20131070","journal-title":"Br J Cancer"},{"issue":"10","key":"2346_CR42","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1158\/1940-6207.CAPR-10-0024","volume":"3","author":"RR Mehta","year":"2010","unstructured":"Mehta RR et al (2010) A 28-Amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesionsp53-mediated inhibition of mouse mammary lesions. Cancer Prevent Res 3(10):1351\u20131360","journal-title":"Cancer Prevent Res"},{"key":"2346_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00280-010-1518-3","volume":"68","author":"L Jia","year":"2011","unstructured":"Jia L et al (2011) Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother Pharmacol 68:513\u2013524","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2346_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/neuonc\/now047","volume":"18","author":"RR Lulla","year":"2016","unstructured":"Lulla RR et al (2016) Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro Oncol 18(9):1319\u20131325","journal-title":"Neuro Oncol"},{"key":"2346_CR45","doi-asserted-by":"publisher","first-page":"106560","DOI":"10.1016\/j.mimet.2022.106560","volume":"200","author":"H Abuei","year":"2022","unstructured":"Abuei H et al (2022) Maximizing the recovery of the native p28 bacterial peptide with improved activity and maintained solubility and stability in Escherichia coli BL21 (DE3). J Microbiol Methods 200:106560","journal-title":"J Microbiol Methods"},{"issue":"10","key":"2346_CR46","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.1021\/acs.jmedchem.2c00417","volume":"65","author":"SA Naffouje","year":"2022","unstructured":"Naffouje SA et al (2022) Nontoxic tumor-targeting optical agents for intraoperative breast tumor imaging. J Med Chem 65(10):7371\u20137379","journal-title":"J Med Chem"},{"issue":"22","key":"2346_CR47","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1039\/D4LC00633J","volume":"24","author":"MC Ceccarelli","year":"2024","unstructured":"Ceccarelli MC et al (2024) Real-time monitoring of a 3D blood\u2013brain barrier model maturation and integrity with a sensorized microfluidic device. Lab Chip 24(22):5085\u20135100","journal-title":"Lab Chip"},{"issue":"1","key":"2346_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0014-4827(88)90265-0","volume":"175","author":"NP Singh","year":"1988","unstructured":"Singh NP et al (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175(1):184\u2013191","journal-title":"Exp Cell Res"},{"issue":"3","key":"2346_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J","volume":"35","author":"RR Tice","year":"2000","unstructured":"Tice RR et al (2000) Single cell gel\/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagenesis 35(3):206\u2013221","journal-title":"Environ Mol Mutagenesis"},{"issue":"9","key":"2346_CR50","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT\u2013PCR. Nucleic Acids Res 29(9):e45\u2013e45","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2346_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13044-024-00202-x","volume":"17","author":"A Kooti","year":"2024","unstructured":"Kooti A et al (2024) Activating transcription factor 3 mediates apoptosis and cell cycle arrest in TP53-mutated anaplastic thyroid cancer cells. Thyroid Res 17(1):12","journal-title":"Thyroid Res"},{"issue":"1","key":"2346_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.59249\/XCAB1680","volume":"98","author":"Z Bagheri","year":"2025","unstructured":"Bagheri Z et al (2025) Inhibition of p16 and NF-\u03baB oncogenic activity in Human Papillomavirus-Infected cervical cancer cells: a new role for Activating Transcription Factor-3. Yale J Biol Med 98(1):21","journal-title":"Yale J Biol Med"},{"issue":"3","key":"2346_CR53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2818.1987.tb02837.x","volume":"147","author":"HJG Gundersen","year":"1987","unstructured":"Gundersen HJG, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147(3):229\u2013263","journal-title":"J Microsc"},{"issue":"1","key":"2346_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12894-022-00964-2","volume":"22","author":"A Farhadi","year":"2022","unstructured":"Farhadi A et al (2022) Epstein-Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma. BMC Urol 22(1):17","journal-title":"BMC Urol"},{"issue":"2","key":"2346_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijpharm.2004.10.007","volume":"288","author":"Q Wang","year":"2005","unstructured":"Wang Q et al (2005) Evaluation of the MDR-MDCK cell line as a permeability screen for the blood\u2013brain barrier. Int J Pharm 288(2):349\u2013359","journal-title":"Int J Pharm"},{"issue":"9","key":"2346_CR56","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A (2019) Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge. Cells 8(9):957","journal-title":"Cells"},{"issue":"5","key":"2346_CR57","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10585-022-10172-9","volume":"39","author":"SU Khan","year":"2022","unstructured":"Khan SU, Fatima K, Malik F (2022) Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metastasis 39(5):715\u2013726","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"2346_CR58","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X et al (2024) Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun 15(1):10232","journal-title":"Nat Commun"},{"issue":"2","key":"2346_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G et al (2022) Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol 19(2):91\u2013113","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2346_CR60","doi-asserted-by":"publisher","first-page":"232","DOI":"10.37349\/etat.2024.00215","volume":"5","author":"P De Santis","year":"2024","unstructured":"De Santis P et al (2024) Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor Target Anti-tumor Ther 5(1):232\u2013250","journal-title":"Explor Target Anti-tumor Ther"},{"key":"2346_CR61","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/j.clinthera.2009.11.011","volume":"31","author":"KHR Tkaczuk","year":"2009","unstructured":"Tkaczuk KHR (2009) Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 31:2273\u20132289","journal-title":"Clin Ther"},{"issue":"7","key":"2346_CR62","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.5812\/semj.85190","volume":"20","author":"H Abuei","year":"2019","unstructured":"Abuei H et al (2019) Construction, expression, and purification of p28 as a cell-penetrating peptide with anticancer effects on Burkitt\u2019s lymphoma cell line. Shiraz E-Med J 20(7):1735\u20131391","journal-title":"Shiraz E-Med J"},{"issue":"12","key":"2346_CR63","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/bjc.2013.266","volume":"108","author":"T Yamada","year":"2013","unstructured":"Yamada T et al (2013) p28, a first in class peptide inhibitor of cop1 binding to p53. Br J Cancer 108(12):2495\u20132504","journal-title":"Br J Cancer"},{"key":"2346_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940001","volume":"12","author":"S Mander","year":"2022","unstructured":"Mander S et al (2022) Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy. Front Oncol 12:940001","journal-title":"Front Oncol"},{"issue":"8","key":"2346_CR65","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-15-2355","volume":"76","author":"T Yamada","year":"2016","unstructured":"Yamada T (2016) p28-mediated activation of p53 in G2\u2013M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy. Cancer Res 76(8):2354\u20132365","journal-title":"Cancer Res"},{"key":"2346_CR66","doi-asserted-by":"publisher","DOI":"10.4065\/84.6.533","volume-title":"Treatment options for breast cancer resistant to anthracycline and taxane","author":"A Moreno-Aspitia","year":"2009","unstructured":"Moreno-Aspitia A, Perez EA (2009) Treatment options for breast cancer resistant to anthracycline and taxane. Elsevier"},{"issue":"11","key":"2346_CR67","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/cancers12113323","volume":"12","author":"SM Maloney","year":"2020","unstructured":"Maloney SM et al (2020) Mechanisms of taxane resistance. Cancers 12(11):3323","journal-title":"Cancers"},{"issue":"1","key":"2346_CR68","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3892\/ijo.2016.3494","volume":"49","author":"S Habata","year":"2016","unstructured":"Habata S et al (2016) BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer. Int J Oncol 49(1):402\u2013410","journal-title":"Int J Oncol"},{"issue":"21","key":"2346_CR69","doi-asserted-by":"publisher","first-page":"8773","DOI":"10.1073\/pnas.1105941108","volume":"108","author":"AT Shaw","year":"2011","unstructured":"Shaw AT et al (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 108(21):8773\u20138778","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2346_CR70","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10456-011-9220-6","volume":"14","author":"RR Mehta","year":"2011","unstructured":"Mehta RR et al (2011) A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 14(3):355\u2013369","journal-title":"Angiogenesis"},{"issue":"11","key":"2346_CR71","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/15384101.2016.1172147","volume":"15","author":"N Bernardes","year":"2016","unstructured":"Bernardes N et al (2016) Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased \u03b21 integrin-mediated adhesion. Cell Cycle 15(11):1415\u20131424","journal-title":"Cell Cycle"},{"issue":"6","key":"2346_CR72","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/jcb.24480","volume":"114","author":"KD Fagan\u2010Solis","year":"2013","unstructured":"Fagan\u2010Solis KD et al (2013) The RhoA pathway mediates MMP\u20102 and MMP\u20109\u2010independent invasive behavior in a triple\u2010negative breast cancer cell line. J Cell Biochem 114(6):1385\u20131394","journal-title":"J Cell Biochem"},{"issue":"1","key":"2346_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/ol.2014.2618","volume":"9","author":"H Li","year":"2015","unstructured":"Li H et al (2015) Ki67 as a predictor of poor prognosis in patients with triple\u2011negative breast cancer. Oncol Lett 9(1):149\u2013152","journal-title":"Oncol Lett"},{"key":"2346_CR74","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2022.02.011","volume":"345","author":"J Wu","year":"2022","unstructured":"Wu J et al (2022) Challenges in delivering therapeutic peptides and proteins: a silk-based solution. J Control Release 345:176\u2013189","journal-title":"J Control Release"},{"issue":"5","key":"2346_CR75","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/pharmaceutics14050907","volume":"14","author":"I Szab\u00f3","year":"2022","unstructured":"Szab\u00f3 I et al (2022) Redesigning of cell-penetrating peptides to improve their efficacy as a drug delivery system. Pharmaceutics 14(5):907","journal-title":"Pharmaceutics"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02346-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02346-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02346-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:03:49Z","timestamp":1779285829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02346-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2346"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02346-7","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments and laboratory procedures were performed in accordance with the relevant guidelines and regulations approved by the Ethics Committee of Shiraz University of Medical Sciences (Approval ID: IR.SUMS.REC. 1398.1298).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"134"}}